The Lancet Infectious Diseases 今日热榜



The Lancet Infectious Diseases The Lancet Infectious Diseases

1.	[Comment] Revisiting MERS-CoV vaccination in the SARS-CoV-2 era	Sarah A Batawi, Basem M Alraddadi	
2.	[Corrections] Correction to Lancet Infect Dis 2021; 21: 823–33		
3.	[Articles] Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial	Matthijs P Raadsen, Christine Dahlke, Anahita Fathi, Svenja Hardtke, Michael Klüver, Verena Krähling, Gesche K Gerresheim, Leonie Mayer, Anna Z Mykytyn, Leonie M Weskamm, Tamara Zoran, Eric C M van Gorp, Gerd Sutter, Stephan Becker, Bart L Haagmans, Marylyn M Addo, MVA-MERS-S_DF-1 Study group	
4.	[Articles] Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial	Yehuda Carmeli, José Miguel Cisneros, Mical Paul, George L Daikos, Minggui Wang, Julian Torre-Cisneros, George Singer, Ivan Titov, Illia Gumenchuk, Yongjie Zhao, Rosa-María Jiménez-Rodríguez, Lu Liang, Gang Chen, Oleksandr Pyptiuk, Firdevs Aksoy, Halley Rogers, Michele Wible, Francis F Arhin, Alison Luckey, Joanne L Leaney, Rienk Pypstra, Joseph W Chow, COMBACTE-CARE consortium REVISIT study group	
5.	[Comment] REVISITing treatment of metallo-β-lactamases	Emily L Heil, Erin K McCreary	
6.	[Review] New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine	Andreas K Lindner, Veerle Lejon, Michael P Barrett, Lucille Blumberg, Salome A Bukachi, Rebecca J Chancey, Andrew Edielu, Lucas Matemba, Tihitina Mesha, Victor Mwanakasale, Christopher Pasi, Tapunda Phiri, Jorge Seixas, Elie A Akl, Katrin Probyn, Gemma Villanueva, Pere P Simarro, Augustin Kadima Ebeja, Jose R Franco, Gerardo Priotto	
7.	[Correspondence] 12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Pad Chivukula, Ye Zhang, Judd L Walson	
8.	[Media Watch] Fail to prepare, prepare to fail	Jessica Pope	
9.	[Media Watch] A shared history	Claire Lenahan	
10.	[Media Watch] COVID-19 and sexual health rights in Africa	Aimee Ramgolam	
11.	[Newsdesk] Médecins Sans Frontières ceases activity in Russia	Ed Holt	
12.	[Comment] Heading in the direction of ending human deaths from dog-mediated rabies	Maria Cristina Schneider, Sofia Sciancalepore	
13.	[Articles] Estimates of the burden of human rabies deaths and animal bites in India, 2022–23: a community-based cross-sectional survey and probability decision-tree modelling study	Jeromie Wesley Vivian Thangaraj, Navaneeth S Krishna, Shanmugasundaram Devika, Suganya Egambaram, Sudha Rani Dhanapal, Siraj Ahmed Khan, Ashok Kumar Srivastava, Ayush Mishra, Basavaraj Shrinivasa, Devendra Gour, Major Madhukar, Nirmal Verma, Parul Sharma, Ravinder Kumar Soni, Sabarinathan Ramasamy, Sreelakshmi Mohandas, Subrata Baidya, Tanveer Rehman, Vijay V Yeldandi, Akashdeep Singh, Aswathy Sreedevi, Babasaheb V Tandale, Debjani Ram Purakayastha, Mahendra M Reddy, Manju Toppo, Nitinkumar Valjibhai Solanki, Pramit Ghosh, Prashant Jaiswal, Shaili Vyas, Shampa Das, Subrata Kumar Palo, Venela Prasanth, Amanda G A Rozario, Chokkalingam Durairajan, Anitha Delli, Aruna Sasi, Chandhini Pandiyan, Doddabale Hanumanthaiah Ashwathnarayana, Sam Joy, Srikrishna Isloor, Mysore Kalappa Sudarshan, Manju Rahi, Manoj V Murhekar, Human Rabies Study Collaborators	
14.	[Correspondence] Preparing for the rapid research response to the possible vertical transmission of Oropouche virus: lessons from a decade of congenital Zika research	Elizabeth B Brickley, Demócrito de Barros Miranda-Filho, Ricardo Arraes de Alencar Ximenes, MERG, ZBC-Consortium, and LIFE Zika Study members	
15.	[Personal View] Advancing the chemotherapy of tuberculous meningitis: a consensus view	Sean Wasserman, Joseph Donovan, Evelyne Kestelyn, James A Watson, Robert E Aarnoutse, James R Barnacle, David R Boulware, Felicia C Chow, Fiona V Cresswell, Angharad G Davis, Kelly E Dooley, Anthony A Figaji, Diana M Gibb, Julie Huynh, Darma Imran, Suzaan Marais, David B Meya, Usha K Misra, Manish Modi, Mihaja Raberahona, Ahmad Rizal Ganiem, Ursula K Rohlwink, Rovina Ruslami, James A Seddon, Keira H Skolimowska, Regan S Solomons, Cari J Stek, Nguyen Thuy Thuong Thuong, Reinout van Crevel, Claire Whitaker, Guy E Thwaites, Robert J Wilkinson	
16.	[Correspondence] Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination	Christine Happle, Markus Hoffmann, Amy Kempf, Inga Nehlmeier, Metodi V Stankov, Noemi Calderon Hampel, Torsten Witte, Stefan Pöhlmann, Georg M N Behrens, Alexandra Dopfer-Jablonka	
17.	[Articles] Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial	Amparo L Figueroa, Dania Torres, Celia Reyes-Acuna, Paul Matherne, Anne Yeakey, Weiping Deng, Wenqin Xu, Yelena Sigal, Greer Chambers, Michelle Olsen, Bethany Girard, Jacqueline M Miller, Rituparna Das, Frances Priddy	
18.	[Comment] COVID-19 immunisation strategies for adolescents	Wei-Xiao Wang, Feng-Cai Zhu	
19.	[Review] The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access	Jonne Terstappen, Sarah F Hak, Anant Bhan, Debby Bogaert, Louis J Bont, Ursula J Buchholz, Andrew D Clark, Cheryl Cohen, Ron Dagan, Daniel R Feikin, Barney S Graham, Anuradha Gupta, Pradeep Haldar, Rose Jalang'o, Ruth A Karron, Leyla Kragten, You Li, Yvette N Löwensteyn, Patrick K Munywoki, Rosemary Njogu, Ab Osterhaus, Andrew J Pollard, Luiza Reali Nazario, Charles Sande, Ashish R Satav, Padmini Srikantiah, Renato T Stein, Naveen Thacker, Rachael Thomas, Marta Tufet Bayona, Natalie I Mazur	
20.	[Review] Optimising vaccine immunogenicity in ageing populations: key strategies	Guangzhen Jiang, Yushu Zou, Dongyu Zhao, Jingyou Yu	
21.	[Personal View] A pox on all our houses: a missing component in the global mpox response is equity	Eddy Jonas, Nesar Hamraz, Nathalie Marcadieu, Daphnee Salomon, Deogratias Niyizonkiza, Jennifer Furin, Jacklin Saint Fleur	
22.	[Comment] Difficulties in diagnosing tuberculosis infection in childhood	Anna Starshinova	
23.	[Media Watch] Globalisation and COVID-19	Matilda Lawson	
24.	[Corrections] Correction to Lancet Infect Dis 2024; published online Sept 10. https://doi.org/10.1016/S1473-3099(24)00585-1		
25.	[Correspondence] Financing infectious disease services in hospitals: a common public good	Joseph D Tucker	
26.	[Articles] Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study	Laura Olbrich, Zoe Franckling-Smith, Leyla Larsson, Issa Sabi, Nyanda Elias Ntinginya, Celso Khosa, Denise Banze, Marriott Nliwasa, Elizabeth Lucy Corbett, Robina Semphere, Valsan Philip Verghese, Joy Sarojini Michael, Marilyn Mary Ninan, Elmar Saathoff, Timothy Daniel McHugh, Alia Razid, Stephen Michael Graham, Rinn Song, Pamela Nabeta, Andre Trollip, Mark Patrick Nicol, Michael Hoelscher, Christof Geldmacher, Norbert Heinrich, Heather Joy Zar, RaPaed-AIDA-TB consortium	
27.	[Media Watch] Vaccine hesitancy in Scandinavia	Hollie Sherwood-Martin	
28.	[Comment] Quantifying the effect of vector targeted interventions to control dengue	Henrik Salje	
29.	[Articles] Mosquito-disseminated pyriproxyfen for mosquito-borne disease control in Belo Horizonte, Brazil: a pragmatic, before–after control–intervention paired-series trial	Fernando Abad-Franch, José Joaquín Carvajal-Cortés, Ana Carolina Lemos Rabelo, Eduardo Viana Vieira Gusmão, Samylla Suany de Souza Soares, Sérgio Luiz Bessa Luz	
30.	[Articles] Temporary adaptations to sexual behaviour during the mpox outbreak in 23 countries in Europe and the Americas: findings from a retrospective cross-sectional online survey	Mateo Prochazka, Pietro Vinti, Ana Hoxha, Andy Seale, Antons Mozalevskis, Rosamund Lewis, Ruben Mayorga Sagastume, Martha Scherzer, Leilia Dore, Meg Doherty	
31.	[Personal View] Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	Richard Kwizera, Alireza Abdolrasouli, Guillermo Garcia-Effron, David W Denning	
32.	[Comment] Mpox control strategies: using behaviour change to complement, not replace, vaccination	Marc C Shamier, Kai J Jonas	
33.	[Articles] Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study	Timothy W Russell, Hermaleigh Townsley, Joel Hellewell, Joshua Gahir, Marianne Shawe-Taylor, David Greenwood, David Hodgson, Agnieszka Hobbs, Giulia Dowgier, Rebecca Penn, Theo Sanderson, Phoebe Stevenson-Leggett, James Bazire, Ruth Harvey, Ashley S Fowler, Murad Miah, Callie Smith, Mauro Miranda, Philip Bawumia, Harriet V Mears, Lorin Adams, Emine Hatipoglu, Nicola O'Reilly, Scott Warchal, Karen Ambrose, Amy Strange, Gavin Kelly, Svend Kjar, Padmasayee Papineni, Tumena Corrah, Richard Gilson, Vincenzo Libri, George Kassiotis, Steve Gamblin, Nicola S Lewis, Bryan Williams, Charles Swanton, Sonia Gandhi, Rupert Beale, Mary Y Wu, David L V Bauer, Edward J Carr, Emma C Wall, Adam J Kucharski	
34.	[Comment] Kinetics of neutralising antibodies against SARS-CoV-2 variants	Piero Poletti	
35.	[Comment] The worsening mpox outbreak in Africa: a call to action	Krutika Kuppalli, Jake Dunning, Inger Damon, Daniel Mukadi-Bamuleka, Placide Mbala, Dimie Ogoina	
36.	[Correspondence] ArboTracker: a multipathogen dashboard and data platform for arbovirus seroprevalence studies	Mairead G Whelan, Harriet Ware, Himanshu Ranka, Sean Kenny, Sabah Shaikh, Yannik Roell, Shaila Akter, Anabel Selemon, Emilie Toews, May Chu, Niklas Bobrovitz, Rahul K Arora, Thomas Jaenisch	
37.	[Correspondence] Mpox outbreak—tecovirimat resistance, management approaches, and challenges in HIV-endemic regions	Wyvine Ansima Bapolisi, Susanne Krasemann, Misaki Wayengera, Bruce Kirenga, Esto Bahizire, Espoir Bwenge Malembaka, Joseph Nelson Siewe Fodjo, Robert Colebunders, Patrick DMC Katoto	
38.	[Comment] SARS-CoV-2 antivirals and post-COVID-19 condition	Ziyad Al-Aly	
39.	[Articles] Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021	GBD 2021 Upper Respiratory Infections Otitis Media Collaborators	
40.	[Articles] Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial	Victoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, Najib M Rahman, Duncan B Richards, Gail Hayward, Jienchi Dorward, David M Lowe, Joseph F Standing, Judith Breuer, Saye Khoo, Stavros Petrou, Kerenza Hood, Haroon Ahmed, Andrew Carson-Stevens, Jonathan S Nguyen-Van-Tam, Mahendra G Patel, Benjamin R Saville, Nick Francis, Nicholas P B Thomas, Philip Evans, Melissa Dobson, May Ee Png, Mark Lown, Oliver van Hecke, Bhautesh D Jani, Nigel D Hart, Daniel Butler, Lucy Cureton, Meena Patil, Monique Andersson, Maria Coates, Clare Bateman, Jennifer C Davies, Ivy Raymundo-Wood, Andrew Ustianowski, Ly-Mee Yu, F D Richard Hobbs, Paul Little, Christopher C Butler, PANORAMIC Trial Collaborative Group	
41.	[Comment] Burden of upper respiratory infections and otitis media	Tal Marom	
42.	[Correspondence] Potential vertical transmission of Oropouche virus during the current outbreak	Athina Samara, Conrado Milani Coutinho, Philip Veal, Jane Osborne, Geraldo Duarte, Shamez Ladhani, Asma Khalil	
43.	[Comment] Next-generation influenza vaccines based on mRNA technology	Irina Isakova-Sivak, Larisa Rudenko	
44.	[Articles] Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50–75 years: a phase 1/2, open-label, randomised trial	Denise Hsu, Akila Jayaraman, Alicia Pucci, Riya Joshi, Kevin Mancini, Hui Ling Chen, Kindra Koslovsky, Xuezhou Mao, Angela Choi, Carole Henry, Jignesh Vakil, Daniel Stadlbauer, Patricia Jorquera, Guha Asthagiri Arunkumar, Nelia E Sanchez-Crespo, L Tyler Wadsworth, Vellore Bhupathy, Evelyn Du, Andrei Avanesov, Jintanat Ananworanich, Raffael Nachbagauer	
45.	[Articles] The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella review	Suzanne M E Kuijpers, David T P Buis, Kirsten A Ziesemer, Reinier M van Hest, Rogier P Schade, Kim C E Sigaloff, Jan M Prins	
46.	[Articles] Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents	Vera Buerger, Sandra Hadl, Martina Schneider, Michaela Schaden, Romana Hochreiter, Annegret Bitzer, Karin Kosulin, Robert Mader, Oliver Zoihsl, Andrea Pfeiffer, Ana Paula Loch, Eolo Morandi, Mauricio Lacerda Nogueira, Carlos Alexandre Antunes de Brito, Julio Croda, Mauro Martins Teixeira, Ivo Castelo-Branco Coelho, Ricardo Gurgel, Allex Jardim da Fonseca, Marcus Vinícius Guimarães de Lacerda, Edson Duarte Moreira, Ana Paula Rocha Veiga, Katrin Dubischar, Nina Wressnigg, Susanne Eder-Lingelbach, Juan Carlos Jaramillo	
47.	[Comment] Shorter antibiotic courses for respiratory tract infections	Javeria Tariq, Ritu Banerjee	
48.	[Comment] First immunogenicity and safety data on live chikungunya vaccine in an endemic area	David O Freedman, Annika Beate Wilder-Smith, Annelies Wilder-Smith	
49.	[Articles] Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial	Flonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, Jennifer D Hamilton, Benjamin A Olenchock, Taylor Brackin, Samit Ganguly, Eduardo Forleo-Neto, Lori Faria, Ingeborg Heirman, Mary Marovich, Julia Hutter, Laura Polakowski, Susan C Irvin, Mazhar Thakur, Andrea T Hooper, Alina Baum, Christopher D Petro, Faisal A Fakih, M Juliana McElrath, Stephen C De Rosa, Kristen W Cohen, LaTonya D Williams, Caleb A Hellman, Ahmad J Odeh, Aloki H Patel, Georgia D Tomaras, Gregory P Geba, Christos A Kyratsous, Bret Musser, George D Yancopoulos, Gary A Herman, Trial Working Group	
50.	[Correspondence] Limitations of mpox lateral flow tests in assessing orthopoxvirus immunity	Toby Jones, Scott Jones, Bethany Hicks, Hannah Selman, Cathy Rowe, Ashley D Otter	
51.	[Comment] Weighing up monoclonals and vaccination against COVID-19	David L V Bauer	
52.	[Correspondence] Mpox—is there a more dangerous new clade?	Christian Hoffmann	
53.	[Correspondence] Oropouche virus genomic surveillance in Brazil	Filipe Romero Rebello Moreira, João Victor Rodrigues Dutra, André Henrique Barbosa de Carvalho, Clarisse Rezende Reis, Jéssica Silqueira Hickson Rios, Marisa de Oliveira Ribeiro, Monica Barcellos Arruda, Patricia Alvarez, Renan Pedra Souza, Carolina Voloch, Danielle Alves Gomes Zauli, Renato Santana Aguiar	
54.	[Correspondence] Oropouche fever: reports of vertical transmission and deaths in Brazil	Paulo Ricardo Martins-Filho, Thialla Andrade Carvalho, Cliomar Alves dos Santos	
55.	[Comment] Assessing the real-world effectiveness of the rVSV-ZEBOV vaccine	Deborah A Williamson, Emma C Thomson	
56.	[Articles] Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study	Sophie Meakin, Justus Nsio, Anton Camacho, Richard Kitenge, Rebecca M Coulborn, Etienne Gignoux, John Johnson, Esther Sterk, Elisabeth Mukamba Musenga, Stephane Hans Bateyi Mustafa, Epicentre-MSF EVD Working Group, Flavio Finger, Steve Ahuka-Mundeke	
57.	[Articles] Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance	Deus S Ishengoma, Celine I Mandara, Catherine Bakari, Abebe A Fola, Rashid A Madebe, Misago D Seth, Filbert Francis, Creyton C Buguzi, Ramadhan Moshi, Issa Garimo, Samwel Lazaro, Abdallah Lusasi, Sijenunu Aaron, Frank Chacky, Ally Mohamed, Ritha J A Njau, Jovin Kitau, Charlotte Rasmussen, Jeffrey A Bailey, Jonathan J Juliano, Marian Warsame	
58.	[Comment] Resistant malaria parasites gaining momentum in Africa	Eulambius M Mlugu, Arjen M Dondorp, Karen I Barnes	
59.	[Comment] Preconception immunisation to prevent pregnancy-associated malaria	Stephanie K Yanow, Daniel Ferrer Vinals	
60.	[Comment] The promising prospects of a new yellow fever vaccine	Anna H E Roukens, Leo G Visser	
61.	[Articles] Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials	Halimatou Diawara, Sara A Healy, Agnes Mwakingwe-Omari, Djibrilla Issiaka, Aye Diallo, Seydou Traore, Ibrahim H Soumbounou, Santara Gaoussou, Irfan Zaidi, Almahamoudou Mahamar, Oumar Attaher, Michal Fried, Blair J Wylie, Rathy Mohan, Viyada Doan, Justin Y A Doritchamou, Amagana Dolo, Robert D Morrison, Jing Wang, Zonghui Hu, Kelly M Rausch, Amatigue Zeguime, Tooba Murshedkar, Natasha KC, B Kim Lee Sim, Peter F Billingsley, Thomas L Richie, Stephen L Hoffman, Alassane Dicko, Patrick E Duffy, PfSPZ Vaccine Study Team	
62.	[Articles] Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial	Kayvon Modjarrad, Paul T Scott, Melanie McCauley, Brittany Ober-Shepherd, Erica Sondergaard, Mihret F Amare, Ajay P Parikh, Badryah Omar, Ada-Marie Minutello, Haritha Adhikarla, Yukun Wu, Andrey Rojas P, Valentine Delore, Nathalie Mantel, Meshell N Morrison, Kamila S Kourbanova, Melissa E Martinez, Ivelese Guzman, Melissa E Greenleaf, Janice M Darden, Michael A Koren, Melinda J Hamer, Christine E Lee, Jack N Hutter, Sheila A Peel, Merlin L Robb, Manuel Vangelisti, Emmanuel Feroldi	
63.	[Articles] Investigating the effect of enhanced cleaning and disinfection of shared medical equipment on health-care-associated infections in Australia (CLEEN): a stepped-wedge, cluster randomised, controlled trial	Katrina Browne, Nicole M White, Philip L Russo, Allen C Cheng, Andrew J Stewardson, Georgia Matterson, Peta E Tehan, Kirsty Graham, Maham Amin, Maria Northcote, Martin Kiernan, Jennie King, David Brain, Brett G Mitchell	
64.	[Articles] Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007–22)	Thi Mui Pham, Yue Zhang, McKenna Nevers, Haojia Li, Karim Khader, Yonatan H Grad, Marc Lipsitch, Matthew Samore	
65.	[Comment] Success of the CLEEN study	Dinah Gould, Nicolas Drey	
66.	[Comment] Antibiotic resistance incidence or proportions: where does the greatest burden lie?	Morgan K Walker, Sameer S Kadri	
67.	[Articles] Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study	Robert McMahon, Sebastian Toepfer, Natascha Sattler, Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl, Romana Hochreiter, Karin Kosulin, Robert Mader, Oliver Zoihsl, Nina Wressnigg, Katrin Dubischar, Vera Buerger, Susanne Eder-Lingelbach, Juan-Carlos Jaramillo	
68.	[Comment] Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	Ernesto T A Marques, Rafael Dhalia	
69.	[Articles] Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial	Paul Kim, Ana M Sanchez, Taylor J R Penke, Hannah H Tuson, James C Kime, Robert W McKee, William L Slone, Nicholas R Conley, Lana J McMillan, Cameron J Prybol, Paul M Garofolo	
70.	[Personal View] The panzootic spread of highly pathogenic avian influenza H5N1 sublineage 2.3.4.4b: a critical appraisal of One Health preparedness and prevention	Marion P G Koopmans, Casey Barton Behravesh, Andrew A Cunningham, Wiku B Adisasmito, Salama Almuhairi, Pépé Bilivogui, Salome A Bukachi, Natalia Casas, Natalia Cediel Becerra, Dominique F Charron, Abhishek Chaudhary, Janice R Ciacci Zanella, Osman Dar, Nitish Debnath, Baptiste Dungu, Elmoubasher Farag, George F Gao, Margaret Khaitsa, Catherine Machalaba, John S Mackenzie, Wanda Markotter, Thomas C Mettenleiter, Serge Morand, Vyacheslav Smolenskiy, Lei Zhou, David T S Hayman, One Health High-Level Expert Panel	
71.	[Articles] Effect of indoor residual spraying on sandfly abundance and incidence of visceral leishmaniasis in India, 2016–22: an interrupted time-series analysis and modelling study	Luc E Coffeng, Sake J de Vlas, Rudra Pratap Singh, Ananthu James, Joy Bindroo, Niteen K Sharma, Asgar Ali, Chandramani Singh, Sadhana Sharma, Michael Coleman	
72.	[Comment] A model of vector-targeted interventions for visceral leishmaniasis	Christine Petersen	
73.	[Review] Ebola virus disease mathematical models and epidemiological parameters: a systematic review	Rebecca K Nash, Sangeeta Bhatia, Christian Morgenstern, Patrick Doohan, David Jorgensen, Kelly McCain, Ruth McCabe, Dariya Nikitin, Alpha Forna, Gina Cuomo-Dannenburg, Joseph T Hicks, Richard J Sheppard, Tristan Naidoo, Sabine van Elsland, Cyril Geismar, Thomas Rawson, Sequoia Iris Leuba, Jack Wardle, Isobel Routledge, Keith Fraser, Pathogen Epidemiology Review Group, Natsuko Imai-Eaton, Anne Cori, H Juliette T Unwin	
74.	[Comment] Edging towards a third dengue vaccine	Annika B Wilder-Smith, David O Freedman, Annelies Wilder-Smith	
75.	[Articles] Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil	Mauricio L Nogueira, Monica A T Cintra, José A Moreira, Elizabeth G Patiño, Patricia Emilia Braga, Juliana C V Tenório, Lucas Bassolli de Oliveira Alves, Vanessa Infante, Daniela Haydee Ramos Silveira, Marcus Vínicius Guimarães de Lacerda, Dhelio Batista Pereira, Allex Jardim da Fonseca, Ricardo Queiroz Gurgel, Ivo Castelo-Branco Coelho, Cor Jesus Fernandes Fontes, Ernesto T A Marques, Gustavo Adolfo Sierra Romero, Mauro Martins Teixeira, André M Siqueira, Viviane Sampaio Boaventura, Fabiano Ramos, Erivaldo Elias Júnior, José Cassio de Moraes, Stephen S Whitehead, Alejandra Esteves-Jaramillo, Tulin Shekar, Jung-Jin Lee, Julieta Macey, Sabrina Gozlan Kelner, Beth-Ann G Coller, Fernanda Castro Boulos, Esper G Kallás, Phase 3 Butantan-DV Working Group	
76.	[Articles] Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial	Ahmed H Fahal, Eiman Siddig Ahmed, Sahar Mubarak Bakhiet, Osama Elhadi Bakhiet, Lamis Ahmed Fahal, Abubakar Ahmed Mohamed, El Semani Widaa Mohamedelamin, Mustafa El Nour Bahar, Hadil Yassir Attalla, Emmanuel Edwar Siddig, Najwa A Mhmoud, Ahmed Mudawi Musa, Wendy W J van de Sande, Bruno Scherrer, Peelen Oyieko, Thaddaeus W Egondi, Kevin O Onyango, Katsura Hata, Wan-Yu Chu, Thomas P C Dorlo, Roger J Brüggemann, Borna A Nyaoke, Nathalie Strub-Wourgaft, Eduard E Zijlstra	
77.	[Comment] Lessons learnt from conducting a randomised clinical trial in eumycetoma	Rosanne Sprute, Oliver A Cornely	
78.	[Articles] Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial	Isabel Leroux-Roels, Chittappen Kandiyil Prajeeth, Amare Aregay, Niranjana Nair, Guus F Rimmelzwaan, Albert D M E Osterhaus, Simone Kardinahl, Sabrina Pelz, Stephan Bauer, Valentino D'Onofrio, Azhar Alhatemi, Bart Jacobs, Fien De Boever, Sharon Porrez, Gwenn Waerlop, Carine Punt, Bart Hendriks, Ellemieke von Mauw, Sandra van de Water, Jose Harders-Westerveen, Barry Rockx, Lucien van Keulen, Jeroen Kortekaas, Geert Leroux-Roels, Paul J Wichgers Schreur	
79.	[Comment] A promising boost for the Rift Valley fever vaccine pipeline	Saskia Bronder, Martina Sester	
80.	[Comment] The need for novel approaches to HIV-1 vaccine development	Clara Lehmann, Philipp Schommers	
81.	[Articles] Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial	Glenda E Gray, Kathryn Mngadi, Ludo Lavreys, Steven Nijs, Peter B Gilbert, John Hural, Ollivier Hyrien, Michal Juraska, Alex Luedtke, Philipp Mann, M Juliana McElrath, Jackline A Odhiambo, Daniel J Stieh, Janine van Duijn, Azwidihwi N Takalani, Wouter Willems, Asa Tapley, Georgia D Tomaras, Johan Van Hoof, Hanneke Schuitemaker, Edith Swann, Dan H Barouch, James G Kublin, Lawrence Corey, Maria G Pau, Susan Buchbinder, Frank Tomaka, Imbokodo/HVTN 705/HPX2008 Study Group	
82.	[Articles] Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial	Santhosh Kumar Ghadge, Martina Schneider, Katrin Dubischar, Laura Wagner, Vera Kadlecek, Michaela Obersriebnig, Romana Hochreiter, Anton Klingler, Julian Larcher-Senn, Ulla Derhaschnig, Wolfgang Bender, Susanne Eder-Lingelbach, Nicole Bézay	
83.	[Comment] Boosting immunity to protect from tickborne Lyme disease	Nicole Baumgarth	
84.	[Articles] Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study	Ming Hong Choi, Eric Yuk Fai Wan, Ian Chi Kei Wong, Esther Wai Yin Chan, Wing Ming Chu, Anthony Raymond Tam, Kwok Yung Yuen, Ivan Fan Ngai Hung	
85.	[Comment] Antiviral therapy for patients with COVID-19: mix and match	Karolina Akinosoglou, Charalambos Gogos	
86.	[Grand Round] Renal transplantation using kidneys from a donor with high grade cytomegalovirus viraemia: case report and literature review	Kasra Shirini, Shani Kamberi, Cynthia Drachenberg, Abdolreza Haririan, Kapil Saharia, Raphael P H Meier	
87.	[Review] The inclusion of children and adolescents in tuberculosis diagnostic development and evaluation–a consensus statement	Else M Bijker, Lyn Horn, Sylvia LaCourse, Emily L MacLean, Ben J Marais, Mark P Nicol, Laura Olbrich, James A Seddon, Jayne S Sutherland, Rinn Song, Heather J Zar, Devan Jaganath, Child TB Diagnostics Consensus Group	
88.	[Personal View] Lassa fever research priorities: towards effective medical countermeasures by the end of the decade	Kristine A Moore, Julia T Ostrowsky, Angela J Mehr, Rebecca A Johnson, Angela K Ulrich, Nicolina M Moua, Petra C Fay, Peter J Hart, Josephine P Golding, Virginia Benassi, Marie-Pierre Preziosi, Ifedayo M Adetifa, George O Akpede, William K Ampofo, Danny A Asogun, Alan D T Barrett, Daniel G Bausch, Ilse de Coster, Devy M Emperador, Heinz Feldmann, Elisabeth Fichet-Calvet, Pierre B H Formenty, Robert F Garry, Donald S Grant, Stephan Günther, Swati B Gupta, Marie Jaspard, Laura T Mazzola, Sylvanus A Okogbenin, Cathy Roth, Connie S Schmaljohn, Michael T Osterholm	
89.	[Personal View] Measures to prevent and treat Nipah virus disease: research priorities for 2024–29	Kristine A Moore, Angela J Mehr, Julia T Ostrowsky, Angela K Ulrich, Nicolina M Moua, Petra C Fay, Peter J Hart, Josephine P Golding, Virginia Benassi, Marie-Pierre Preziosi, Christopher C Broder, Emmie de Wit, Pierre B H Formenty, Alexander N Freiberg, Emily S Gurley, Kim Halpin, Stephen P Luby, Laura T Mazzola, Joel M Montgomery, Christina F Spiropoulou, Devendra T Mourya, Shahana Parveen, Mahmudur Rahman, Cathy Roth, Lin-Fa Wang, Michael T Osterholm	

更新于 59 分钟前

近期历史最近 100 条记录

2024-10-08	[Comment] Revisiting MERS-CoV vaccination in the SARS-CoV-2 era	Sarah A Batawi, Basem M Alraddadi	
2024-10-08	[Corrections] Correction to Lancet Infect Dis 2021; 21: 823–33		
2024-10-08	[Articles] Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial	Matthijs P Raadsen, Christine Dahlke, Anahita Fathi, Svenja Hardtke, Michael Klüver, Verena Krähling, Gesche K Gerresheim, Leonie Mayer, Anna Z Mykytyn, Leonie M Weskamm, Tamara Zoran, Eric C M van Gorp, Gerd Sutter, Stephan Becker, Bart L Haagmans, Maryl	
2024-10-08	[Articles] Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial	Yehuda Carmeli, José Miguel Cisneros, Mical Paul, George L Daikos, Minggui Wang, Julian Torre-Cisneros, George Singer, Ivan Titov, Illia Gumenchuk, Yongjie Zhao, Rosa-María Jiménez-Rodríguez, Lu Liang, Gang Chen, Oleksandr Pyptiuk, Firdevs Aksoy, Halley R	
2024-10-08	[Comment] REVISITing treatment of metallo-β-lactamases	Emily L Heil, Erin K McCreary	
2024-10-08	[Review] New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine	Andreas K Lindner, Veerle Lejon, Michael P Barrett, Lucille Blumberg, Salome A Bukachi, Rebecca J Chancey, Andrew Edielu, Lucas Matemba, Tihitina Mesha, Victor Mwanakasale, Christopher Pasi, Tapunda Phiri, Jorge Seixas, Elie A Akl, Katrin Probyn, Gemma Vi	
2024-10-08	[Correspondence] 12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Pad Chivukula, Ye Zhang, Judd L Walson	
2024-10-05	[Media Watch] Fail to prepare, prepare to fail	Jessica Pope	
2024-10-05	[Media Watch] A shared history	Claire Lenahan	
2024-10-04	[Media Watch] COVID-19 and sexual health rights in Africa	Aimee Ramgolam	
2024-10-04	[Newsdesk] Médecins Sans Frontières ceases activity in Russia	Ed Holt	
2024-10-01	[Comment] Heading in the direction of ending human deaths from dog-mediated rabies	Maria Cristina Schneider, Sofia Sciancalepore	
2024-10-01	[Articles] Estimates of the burden of human rabies deaths and animal bites in India, 2022–23: a community-based cross-sectional survey and probability decision-tree modelling study	Jeromie Wesley Vivian Thangaraj, Navaneeth S Krishna, Shanmugasundaram Devika, Suganya Egambaram, Sudha Rani Dhanapal, Siraj Ahmed Khan, Ashok Kumar Srivastava, Ayush Mishra, Basavaraj Shrinivasa, Devendra Gour, Major Madhukar, Nirmal Verma, Parul Sharma,	
2024-09-28	[Correspondence] Preparing for the rapid research response to the possible vertical transmission of Oropouche virus: lessons from a decade of congenital Zika research	Elizabeth B Brickley, Demócrito de Barros Miranda-Filho, Ricardo Arraes de Alencar Ximenes, MERG, ZBC-Consortium, and LIFE Zika Study members	
2024-09-27	[Personal View] Advancing the chemotherapy of tuberculous meningitis: a consensus view	Sean Wasserman, Joseph Donovan, Evelyne Kestelyn, James A Watson, Robert E Aarnoutse, James R Barnacle, David R Boulware, Felicia C Chow, Fiona V Cresswell, Angharad G Davis, Kelly E Dooley, Anthony A Figaji, Diana M Gibb, Julie Huynh, Darma Imran, Suzaan	
2024-09-26	[Correspondence] Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination	Christine Happle, Markus Hoffmann, Amy Kempf, Inga Nehlmeier, Metodi V Stankov, Noemi Calderon Hampel, Torsten Witte, Stefan Pöhlmann, Georg M N Behrens, Alexandra Dopfer-Jablonka	
2024-09-25	[Articles] Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial	Amparo L Figueroa, Dania Torres, Celia Reyes-Acuna, Paul Matherne, Anne Yeakey, Weiping Deng, Wenqin Xu, Yelena Sigal, Greer Chambers, Michelle Olsen, Bethany Girard, Jacqueline M Miller, Rituparna Das, Frances Priddy	
2024-09-25	[Comment] COVID-19 immunisation strategies for adolescents	Wei-Xiao Wang, Feng-Cai Zhu	
2024-09-24	[Review] The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access	Jonne Terstappen, Sarah F Hak, Anant Bhan, Debby Bogaert, Louis J Bont, Ursula J Buchholz, Andrew D Clark, Cheryl Cohen, Ron Dagan, Daniel R Feikin, Barney S Graham, Anuradha Gupta, Pradeep Haldar, Rose Jalang'o, Ruth A Karron, Leyla Kragten, You Li, Yvet	
2024-09-24	[Review] Optimising vaccine immunogenicity in ageing populations: key strategies	Guangzhen Jiang, Yushu Zou, Dongyu Zhao, Jingyou Yu	
2024-09-24	[Personal View] A pox on all our houses: a missing component in the global mpox response is equity	Eddy Jonas, Nesar Hamraz, Nathalie Marcadieu, Daphnee Salomon, Deogratias Niyizonkiza, Jennifer Furin, Jacklin Saint Fleur	
2024-09-21	[Comment] Difficulties in diagnosing tuberculosis infection in childhood	Anna Starshinova	
2024-09-21	[Media Watch] Globalisation and COVID-19	Matilda Lawson	
2024-09-21	[Corrections] Correction to Lancet Infect Dis 2024; published online Sept 10. https://doi.org/10.1016/S1473-3099(24)00585-1		
2024-09-21	[Articles] Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study	Laura Olbrich, Zoe Franckling-Smith, Leyla Larsson, Issa Sabi, Nyanda Elias Ntinginya, Celso Khosa, Denise Banze, Marriott Nliwasa, Elizabeth Lucy Corbett, Robina Semphere, Valsan Philip Verghese, Joy Sarojini Michael, Marilyn Mary Ninan, Elmar Saathoff,	
2024-09-21	[Correspondence] Financing infectious disease services in hospitals: a common public good	Joseph D Tucker	
2024-09-21	[Media Watch] Vaccine hesitancy in Scandinavia	Hollie Sherwood-Martin	
2024-09-20	[Articles] Mosquito-disseminated pyriproxyfen for mosquito-borne disease control in Belo Horizonte, Brazil: a pragmatic, before–after control–intervention paired-series trial	Fernando Abad-Franch, José Joaquín Carvajal-Cortés, Ana Carolina Lemos Rabelo, Eduardo Viana Vieira Gusmão, Samylla Suany de Souza Soares, Sérgio Luiz Bessa Luz	
2024-09-20	[Comment] Quantifying the effect of vector targeted interventions to control dengue	Henrik Salje	
2024-09-19	[Articles] Temporary adaptations to sexual behaviour during the mpox outbreak in 23 countries in Europe and the Americas: findings from a retrospective cross-sectional online survey	Mateo Prochazka, Pietro Vinti, Ana Hoxha, Andy Seale, Antons Mozalevskis, Rosamund Lewis, Ruben Mayorga Sagastume, Martha Scherzer, Leilia Dore, Meg Doherty	
2024-09-19	[Personal View] Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	Richard Kwizera, Alireza Abdolrasouli, Guillermo Garcia-Effron, David W Denning	
2024-09-19	[Comment] Mpox control strategies: using behaviour change to complement, not replace, vaccination	Marc C Shamier, Kai J Jonas	
2024-09-13	[Newsdesk] Polio vaccination campaign in Gaza	Talha Burki	
2024-09-12	[Articles] Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study	Timothy W Russell, Hermaleigh Townsley, Joel Hellewell, Joshua Gahir, Marianne Shawe-Taylor, David Greenwood, David Hodgson, Agnieszka Hobbs, Giulia Dowgier, Rebecca Penn, Theo Sanderson, Phoebe Stevenson-Leggett, James Bazire, Ruth Harvey, Ashley S Fowle	
2024-09-12	[Comment] Kinetics of neutralising antibodies against SARS-CoV-2 variants	Piero Poletti	
2024-09-11	[Comment] The worsening mpox outbreak in Africa: a call to action	Krutika Kuppalli, Jake Dunning, Inger Damon, Daniel Mukadi-Bamuleka, Placide Mbala, Dimie Ogoina	
2024-09-11	[Correspondence] ArboTracker: a multipathogen dashboard and data platform for arbovirus seroprevalence studies	Mairead G Whelan, Harriet Ware, Himanshu Ranka, Sean Kenny, Sabah Shaikh, Yannik Roell, Shaila Akter, Anabel Selemon, Emilie Toews, May Chu, Niklas Bobrovitz, Rahul K Arora, Thomas Jaenisch	
2024-09-11	[Correspondence] Mpox outbreak—tecovirimat resistance, management approaches, and challenges in HIV-endemic regions	Wyvine Ansima Bapolisi, Susanne Krasemann, Misaki Wayengera, Bruce Kirenga, Esto Bahizire, Espoir Bwenge Malembaka, Joseph Nelson Siewe Fodjo, Robert Colebunders, Patrick DMC Katoto	
2024-09-10	[Articles] Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021	GBD 2021 Upper Respiratory Infections Otitis Media Collaborators	
2024-09-10	[Comment] SARS-CoV-2 antivirals and post-COVID-19 condition	Ziyad Al-Aly	
2024-09-10	[Articles] Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial	Victoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, Najib M Rahman, Duncan B Richards, Gail Hayward, Jienchi Dorward, David M Lowe, Joseph F Standing, Judith Breuer, Saye Khoo, Stavros Petrou, Kerenza Hood, Haroon Ahmed, Andrew Carson-Stevens, Jon	
2024-09-10	[Comment] Burden of upper respiratory infections and otitis media	Tal Marom	
2024-09-10	[Correspondence] Potential vertical transmission of Oropouche virus during the current outbreak	Athina Samara, Conrado Milani Coutinho, Philip Veal, Jane Osborne, Geraldo Duarte, Shamez Ladhani, Asma Khalil	
2024-09-07	[Newsdesk] Mpox emergency in Africa	Esther Nakkazi	
2024-09-06	[Comment] Next-generation influenza vaccines based on mRNA technology	Irina Isakova-Sivak, Larisa Rudenko	
2024-09-06	[Articles] Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50–75 years: a phase 1/2, open-label, randomised trial	Denise Hsu, Akila Jayaraman, Alicia Pucci, Riya Joshi, Kevin Mancini, Hui Ling Chen, Kindra Koslovsky, Xuezhou Mao, Angela Choi, Carole Henry, Jignesh Vakil, Daniel Stadlbauer, Patricia Jorquera, Guha Asthagiri Arunkumar, Nelia E Sanchez-Crespo, L Tyler W	
2024-09-05	[Articles] The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella review	Suzanne M E Kuijpers, David T P Buis, Kirsten A Ziesemer, Reinier M van Hest, Rogier P Schade, Kim C E Sigaloff, Jan M Prins	
2024-09-05	[Articles] Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents	Vera Buerger, Sandra Hadl, Martina Schneider, Michaela Schaden, Romana Hochreiter, Annegret Bitzer, Karin Kosulin, Robert Mader, Oliver Zoihsl, Andrea Pfeiffer, Ana Paula Loch, Eolo Morandi, Mauricio Lacerda Nogueira, Carlos Alexandre Antunes de Brito, Ju	
2024-09-05	[Comment] Shorter antibiotic courses for respiratory tract infections	Javeria Tariq, Ritu Banerjee	
2024-09-05	[Comment] First immunogenicity and safety data on live chikungunya vaccine in an endemic area	David O Freedman, Annika Beate Wilder-Smith, Annelies Wilder-Smith	
2024-09-03	[Articles] Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial	Flonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, Jennifer D Hamilton, Benjamin A Olenchock, Taylor Brackin, Samit Ganguly, Eduardo Forleo-Neto, Lori Faria, Ingeborg Heirman, Mary Marovich, Julia Hutter, Laura Polakowski, Susan C Irvin, Mazhar Thakur, And	
2024-09-03	[Correspondence] Limitations of mpox lateral flow tests in assessing orthopoxvirus immunity	Toby Jones, Scott Jones, Bethany Hicks, Hannah Selman, Cathy Rowe, Ashley D Otter	
2024-09-03	[Comment] Weighing up monoclonals and vaccination against COVID-19	David L V Bauer	
2024-09-03	[Media Watch] Facing COVID-19 in South Africa	Jonathan Blott	
2024-08-29	[Correspondence] Mpox—is there a more dangerous new clade?	Christian Hoffmann	
2024-08-28	[Media Watch] Biopolitical precarity for women with HIV in South Africa	Emma Starbuck	
2024-08-28	[Media Watch] Antiblackness in the Ebola response in Sierra Leone	Elizabeth Haslam	
2024-08-28	[Corrections] Correction to Lancet Infect Dis 2024; published online Aug 12. https://doi.org/10.1016/S1473-3099(24)00357-8		
2024-08-27	[Correspondence] Oropouche virus genomic surveillance in Brazil	Filipe Romero Rebello Moreira, João Victor Rodrigues Dutra, André Henrique Barbosa de Carvalho, Clarisse Rezende Reis, Jéssica Silqueira Hickson Rios, Marisa de Oliveira Ribeiro, Monica Barcellos Arruda, Patricia Alvarez, Renan Pedra Souza, Carolina Voloc	
2024-08-23	[Correspondence] Oropouche fever: reports of vertical transmission and deaths in Brazil	Paulo Ricardo Martins-Filho, Thialla Andrade Carvalho, Cliomar Alves dos Santos	
2024-08-22	[Correspondence] Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south	Dhammika Leshan Wannigama, Mohan Amarasiri, Phatthranit Phattharapornjaroen, Cameron Hurst, Charin Modchang, John Jefferson V Besa, Kazuhiko Miyanaga, Longzhu Cui, Stefan Fernandez, Angkana T Huang, Puey Ounjai, Pathogen Hunters Research Team, Andrew C Si	
2024-08-22	[Correspondence] Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance	Thibaut Vanbaelen, Sheeba Santhini Manoharan-Basil, Chris Kenyon	
2024-08-22	[Comment] Re-evaluating polio vaccination strategies in Nepal: transitioning from OPV to fIPV for sustained immunity	Bhuvan Saud, Saroj Adhikari	
2024-08-21	[Comment] Assessing the real-world effectiveness of the rVSV-ZEBOV vaccine	Deborah A Williamson, Emma C Thomson	
2024-08-21	[Articles] Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study	Sophie Meakin, Justus Nsio, Anton Camacho, Richard Kitenge, Rebecca M Coulborn, Etienne Gignoux, John Johnson, Esther Sterk, Elisabeth Mukamba Musenga, Stephane Hans Bateyi Mustafa, Epicentre-MSF EVD Working Group, Flavio Finger, Steve Ahuka-Mundeke	
2024-08-21	[Correspondence] The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus	Min Du, Min Liu, Ben Niu, Jue Liu	
2024-08-17	[Correspondence] Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant	Yu Kaku, Keiya Uriu, Kaho Okumura, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Jumpei Ito, Kei Sato	
2024-08-17	[Media Watch] Tuberculosis in the USA in 1935	Sanjeet Bagcchi	
2024-08-17	[Media Watch] Understanding outbreak preparedness	Manjulika Das	
2024-08-17	[Articles] Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance	Deus S Ishengoma, Celine I Mandara, Catherine Bakari, Abebe A Fola, Rashid A Madebe, Misago D Seth, Filbert Francis, Creyton C Buguzi, Ramadhan Moshi, Issa Garimo, Samwel Lazaro, Abdallah Lusasi, Sijenunu Aaron, Frank Chacky, Ally Mohamed, Ritha J A Njau,	
2024-08-17	[Comment] Resistant malaria parasites gaining momentum in Africa	Eulambius M Mlugu, Arjen M Dondorp, Karen I Barnes	
2024-08-15	[Articles] Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials	Halimatou Diawara, Sara A Healy, Agnes Mwakingwe-Omari, Djibrilla Issiaka, Aye Diallo, Seydou Traore, Ibrahim H Soumbounou, Santara Gaoussou, Irfan Zaidi, Almahamoudou Mahamar, Oumar Attaher, Michal Fried, Blair J Wylie, Rathy Mohan, Viyada Doan, Justin Y	
2024-08-15	[Comment] Preconception immunisation to prevent pregnancy-associated malaria	Stephanie K Yanow, Daniel Ferrer Vinals	
2024-08-15	[Articles] Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial	Kayvon Modjarrad, Paul T Scott, Melanie McCauley, Brittany Ober-Shepherd, Erica Sondergaard, Mihret F Amare, Ajay P Parikh, Badryah Omar, Ada-Marie Minutello, Haritha Adhikarla, Yukun Wu, Andrey Rojas P, Valentine Delore, Nathalie Mantel, Meshell N Morris	
2024-08-15	[Comment] The promising prospects of a new yellow fever vaccine	Anna H E Roukens, Leo G Visser	
2024-08-14	[Articles] Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007–22)	Thi Mui Pham, Yue Zhang, McKenna Nevers, Haojia Li, Karim Khader, Yonatan H Grad, Marc Lipsitch, Matthew Samore	
2024-08-14	[Comment] Success of the CLEEN study	Dinah Gould, Nicolas Drey	
2024-08-14	[Articles] Investigating the effect of enhanced cleaning and disinfection of shared medical equipment on health-care-associated infections in Australia (CLEEN): a stepped-wedge, cluster randomised, controlled trial	Katrina Browne, Nicole M White, Philip L Russo, Allen C Cheng, Andrew J Stewardson, Georgia Matterson, Peta E Tehan, Kirsty Graham, Maham Amin, Maria Northcote, Martin Kiernan, Jennie King, David Brain, Brett G Mitchell	
2024-08-14	[Comment] Antibiotic resistance incidence or proportions: where does the greatest burden lie?	Morgan K Walker, Sameer S Kadri	
2024-08-14	[Correspondence] Enhancing wastewater testing for H5N1 surveillance	Ranu S Dhillon, Abraar Karan, Devabhaktuni Srikrishna	
2024-08-14	[Correspondence] Gonorrhoea and chlamydia screening for asymptomatic people with HIV and HIV PrEP users: open issues	Angelo Roberto Raccagni, Antonella Castagna, Silvia Nozza	
2024-08-13	[Articles] Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study	Robert McMahon, Sebastian Toepfer, Natascha Sattler, Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl, Romana Hochreiter, Karin Kosulin, Robert Mader, Oliver Zoihsl, Nina Wressnigg, Katrin Dubischar, Vera Buerger, Susanne Eder-Lingelbach, Juan-Carl	
2024-08-13	[Comment] Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	Ernesto T A Marques, Rafael Dhalia	
2024-08-10	[Articles] Effect of indoor residual spraying on sandfly abundance and incidence of visceral leishmaniasis in India, 2016–22: an interrupted time-series analysis and modelling study	Luc E Coffeng, Sake J de Vlas, Rudra Pratap Singh, Ananthu James, Joy Bindroo, Niteen K Sharma, Asgar Ali, Chandramani Singh, Sadhana Sharma, Michael Coleman	
2024-08-10	[Articles] Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase	Paul Kim, Ana M Sanchez, Taylor J R Penke, Hannah H Tuson, James C Kime, Robert W McKee, William L Slone, Nicholas R Conley, Lana J McMillan, Cameron J Prybol, Paul M Garofolo	
2024-08-10	[Personal View] The panzootic spread of highly pathogenic avian influenza H5N1 sublineage 2.3.4.4b: a critical appraisal of One Health preparedness and prevention	Marion P G Koopmans, Casey Barton Behravesh, Andrew A Cunningham, Wiku B Adisasmito, Salama Almuhairi, Pépé Bilivogui, Salome A Bukachi, Natalia Casas, Natalia Cediel Becerra, Dominique F Charron, Abhishek Chaudhary, Janice R Ciacci Zanella, Osman Dar, Ni	
2024-08-10	[Comment] A model of vector-targeted interventions for visceral leishmaniasis	Christine Petersen	
2024-08-09	[Editorial] Oropouche fever, the mysterious threat	The Lancet Infectious Diseases	
2024-08-08	[Review] Ebola virus disease mathematical models and epidemiological parameters: a systematic review	Rebecca K Nash, Sangeeta Bhatia, Christian Morgenstern, Patrick Doohan, David Jorgensen, Kelly McCain, Ruth McCabe, Dariya Nikitin, Alpha Forna, Gina Cuomo-Dannenburg, Joseph T Hicks, Richard J Sheppard, Tristan Naidoo, Sabine van Elsland, Cyril Geismar,	
2024-08-08	[Correspondence] Emergence of an extensively drug-resistant Neisseria gonorrhoeae clone	Sebastiaan J van Hal, Norelle Sherry, Geoff Coombs, Shakeel Mowlaboccus, David M Whiley, Monica M Lahra	
2024-08-08	[Correspondence] First diagnoses of Oropouche virus in Europe: how can we strengthen communication and preparedness globally?	Concetta Castilletti, Antonio Mori, Elena Pomari, Andrea Matucci, Giulia Martelli, Salvatore Curiale, Andrea Angheben, Federico Giovanni Gobbi	
2024-08-06	[Comment] Edging towards a third dengue vaccine	Annika B Wilder-Smith, David O Freedman, Annelies Wilder-Smith	
2024-08-06	[Articles] Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil	Mauricio L Nogueira, Monica A T Cintra, José A Moreira, Elizabeth G Patiño, Patricia Emilia Braga, Juliana C V Tenório, Lucas Bassolli de Oliveira Alves, Vanessa Infante, Daniela Haydee Ramos Silveira, Marcus Vínicius Guimarães de Lacerda, Dhelio Batista	
2024-08-03	[Correspondence] Tracking the spread of avian influenza A(H5N1) with alternative surveillance methods: the example of wastewater data	Francesco Branda, Massimo Ciccozzi, Fabio Scarpa	
2024-08-02	[Articles] Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial	Ahmed H Fahal, Eiman Siddig Ahmed, Sahar Mubarak Bakhiet, Osama Elhadi Bakhiet, Lamis Ahmed Fahal, Abubakar Ahmed Mohamed, El Semani Widaa Mohamedelamin, Mustafa El Nour Bahar, Hadil Yassir Attalla, Emmanuel Edwar Siddig, Najwa A Mhmoud, Ahmed Mudawi Musa	
2024-08-02	[Comment] Lessons learnt from conducting a randomised clinical trial in eumycetoma	Rosanne Sprute, Oliver A Cornely	
2024-08-01	[Corrections] Correction to Lancet Infect Dis 2024; 24: e484		
2024-07-30	[Media Watch] Anthony Fauci: a life on page	Bipin Adhikari, Lorenz Von Seidlein	
2024-07-26	[Articles] Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial	Isabel Leroux-Roels, Chittappen Kandiyil Prajeeth, Amare Aregay, Niranjana Nair, Guus F Rimmelzwaan, Albert D M E Osterhaus, Simone Kardinahl, Sabrina Pelz, Stephan Bauer, Valentino D'Onofrio, Azhar Alhatemi, Bart Jacobs, Fien De Boever, Sharon Porrez, Gw	
2024-07-26	[Comment] A promising boost for the Rift Valley fever vaccine pipeline	Saskia Bronder, Martina Sester	